I spend a lot of time in conversations with banks and wealth managers about AI. What models to deploy, what workflows to automate, what compliance frameworks to build. Practical stuff. Near-term stuff.

But there is a question I keep raising that gets blank stares from almost every financial executive I talk to: what happens to your entire business when your clients stop dying on schedule?

This is not a thought experiment. It is happening right now, driven by science that has moved from speculative to clinical in under five years. And the financial services industry -- an industry that runs on actuarial assumptions about human mortality -- is almost completely unprepared.

The science is no longer speculative

Let me be specific about what has changed, because the details matter.

GLP-1 receptor agonists -- semaglutide, tirzepatide -- started as diabetes drugs. Then they turned out to reduce cardiovascular events by 20%. Then kidney disease. Then, in emerging data, they appear to reduce all-cause mortality. These are not marginal effects. A drug class that simultaneously addresses obesity, heart disease, and metabolic syndrome is, from a population health standpoint, the most significant pharmaceutical development in decades.

Senolytics -- drugs that clear senescent "zombie" cells from your body -- are in clinical trials right now. Unity Biotechnology, Oisin Biotechnologies, and Senolytic Therapeutics are all running human studies. The animal data has been striking: cleared senescent cells, reversed age-related tissue decline, extended healthspan. The first human results are expected within 18 months.

Gene therapy has moved from theory to treatment. Verve Therapeutics is running a trial for a single-injection gene edit that permanently lowers LDL cholesterol. One shot. Lifetime effect. No more statins. Imagine that scaled to other age-related conditions.

And then there is the money. Bryan Johnson, the tech entrepreneur, spends roughly $2 million per year on a systematic anti-aging protocol and has documented measurable biological age reversal. You can argue with his methods. You cannot argue with the trend he represents: wealthy individuals are already treating aging as an engineering problem, not a fate.

Altos Labs raised $3 billion to work on cellular reprogramming -- turning old cells young again. That single raise was larger than the entire longevity sector's funding five years ago. Retro Biosciences, backed by Sam Altman, is pursuing the same goal. Calico, Alphabet's longevity company, has been running since 2013 with functionally unlimited resources. Saudi Arabia's Hevolution Foundation committed $1 billion per year -- not a fund, an annual commitment -- to longevity research.

This is not fringe science. This is where some of the most sophisticated capital in the world is going.

The pension math problem

Here is the core issue for financial services, stated plainly.

Every pension fund in the world runs its models on mortality tables. Those tables say a 65-year-old man in Western Europe will live, on average, to about 83. A woman to about 86. The entire liability structure -- how much the fund needs to pay out, for how long, and therefore how much it needs to have invested -- is calibrated to those numbers.

Now shift those numbers by fifteen years. A man lives to 98. A woman to 101. The pension fund that expected to pay benefits for 18 years now pays for 33 years. That is not a small adjustment. That is an 83% increase in total liability.

No pension fund on earth is funded for that scenario. Not one.

The UK's Pension Protection Fund oversees roughly 5,300 schemes. Their 2025 stress tests modeled a two-year increase in life expectancy as a significant risk scenario. Two years. The science I just described could deliver ten to twenty. The gap between what pension actuaries are stress-testing and what biology is delivering is enormous.

Japan is the preview. The Government Pension Investment Fund -- the largest pension fund in the world at $1.6 trillion -- has had to completely restructure its asset allocation over the past decade. Japanese life expectancy is already 84.7 and climbing. Their pension math broke years ago. They just have not admitted it publicly.

Italy, where I am based, has a median age of 48.4. We are essentially Japan with better food and worse pension math.

Insurance repricing: the quiet crisis

Life insurance is the sector most directly exposed to longevity risk, and the one doing the least about it.

The entire business model is simple: the insurer bets on when you die, collects premiums based on that bet, and the actuarial math keeps the company profitable. If the "when" shifts by fifteen years for a meaningful portion of policyholders, the math breaks.

But it is not just life insurance. Health insurance faces a different version of the same problem. If people live to 100 but spend their last 20 years managing chronic conditions, health insurers face decades of additional claims per policyholder. If, on the other hand, the new science extends healthspan -- healthy years, not just years -- then health costs might actually decline per year of life but extend over a much longer period. Either scenario requires fundamentally different pricing models.

Disability insurance faces a version too. If the retirement age stays at 65 but health allows people to work productively until 80, the entire concept of disability needs rethinking. Long-term care insurance, already a troubled product category, becomes either far more expensive or far less necessary, depending on whether the longevity gains are healthy years or frail years.

Some insurers are moving. Swiss Re has been publishing research on longevity risk since 2019. Prudential launched a dedicated longevity risk division. The UK longevity swap market -- instruments that let pension funds transfer longevity risk to capital markets -- hit roughly $50 billion in notional value. But these are hedges. They are defensive moves by companies trying to offload risk they do not understand yet.

The real opportunity is offensive: building insurance products designed for people who expect to live to 100. Health-linked premiums that adjust based on biomarker data. Coverage structures that span 60 years of adulthood instead of 40. The insurer that cracks this first owns the market.

Wealth management needs a new framework

I sell AI to wealth managers. I sit in their offices. I see their planning tools. And I can tell you with certainty: almost none of them are modeling for clients who live past 90.

The standard retirement planning conversation is: you retire at 65, you need income for 20 years, here is your drawdown rate. The 4% rule -- the bedrock of retirement planning for thirty years -- was designed for a 30-year retirement horizon. What happens at year 40? Year 50?

The answer is: you run out of money. This is not hypothetical. It is already happening to people who retired in the early 2000s and are now in their late 80s, watching their savings evaporate because nobody planned for them still being alive.

The single biggest financial risk for the next generation of retirees is not market volatility. It is outliving their portfolio.

A 40-year retirement instead of a 20-year retirement requires completely different products. More allocation to growth assets in later life -- the conventional wisdom of shifting entirely to bonds at 65 becomes dangerous when you have 35 years left. More annuity-like income streams that cannot be outlived. Dynamic withdrawal strategies that adapt to health data, not just market data. Multi-generational wealth planning that accounts for the possibility that three generations might be alive simultaneously, all with competing financial needs.

And the advisory model itself changes. A financial advisor who builds a plan at age 50 and checks in annually is inadequate for a client who might live another 50 years through multiple economic cycles, technology shifts, and health transitions. This is where AI becomes essential -- not as a replacement for advisors, but as the only tool capable of continuously modeling the interaction between health data, market conditions, inflation trajectories, healthcare costs, and longevity projections for each individual client.

The longevity economy is already $8.3 trillion

This is not a future market. It exists today.

Oxford Economics estimated the global longevity economy at $8.3 trillion, with projections reaching $27 trillion by 2026. AARP estimated spending by and on behalf of people over 50 at $22 trillion in 2024 -- the third-largest economy in the world if treated as a country, behind only the US and China.

But the old longevity economy was about aging populations buying things. The new longevity economy is about people who do not just live longer but live longer healthy. Healthspan, not just lifespan. And the financial products for this new population do not exist yet.

Consider what is needed. Longevity bonds -- fixed income instruments whose payoff is linked to population survival rates. Healthspan insurance -- policies that pay out not when you die, but when your health declines below a measurable threshold. Biological age-indexed products -- financial instruments priced on your actual biological age, measured by epigenetic clocks, rather than your chronological age. Multi-generational wealth vehicles designed for families where great-grandparents and great-grandchildren are both alive and both have financial needs.

None of these products exist at scale today. The institution that builds them first captures a market that will be measured in trillions.

The Gulf angle

There is a geographic dimension to this that most Western financial institutions are missing.

The Gulf states are making longevity a strategic priority. Saudi Arabia's NEOM project includes a dedicated biotech and health innovation zone. The Hevolution Foundation, which I mentioned earlier, is a Saudi sovereign commitment to longevity science that dwarfs most Western government spending on the topic. The UAE has launched multiple health and longevity initiatives, including the Dubai Future Foundation's focus on extending healthy human life.

This is not philanthropy. These are countries with young populations, enormous sovereign wealth, and a strategic interest in building post-oil economies. Longevity science and longevity finance are part of that transition. The Gulf is positioning itself as a global hub for both the science and the financial products that will emerge from it.

For European and American financial institutions, this matters because it means the competition for longevity-native financial products will not come only from Silicon Valley biotech firms. It will come from sovereign-backed institutions in the Gulf with patient capital and long time horizons -- exactly the kind of capital that longevity products require.

New products for a new reality

Let me be concrete about what the financial services industry needs to build.

First, longevity-adjusted retirement products. Every target-date fund, every drawdown strategy, every retirement income product needs to be re-engineered for a 40-year retirement horizon. This is not an incremental change. It requires different asset allocation, different risk models, different fee structures.

Second, health-linked financial instruments. Products whose pricing, payouts, or terms adjust based on verified health data -- biological age scores, biomarker panels, health behavior data. The technology to measure this reliably exists today. The financial products do not.

Third, longevity risk transfer mechanisms at scale. The $50 billion UK longevity swap market needs to become a $5 trillion global market. Pension funds, insurers, and governments all need ways to hedge longevity risk, and capital markets need to provide them.

Fourth, multi-generational wealth planning tools. When four generations are alive simultaneously, wealth transfer becomes exponentially more complex. Tax planning, estate planning, trust structures -- all need to be rethought for families that span a century.

Fifth, longevity as an investable theme. Asset managers need dedicated longevity funds that invest across the value chain: biotech companies developing the science, healthcare companies delivering the treatments, financial companies building the products, and real estate and consumer companies serving the longest-lived population in human history.

The bank that moves first wins

I have raised this topic with C-level executives at maybe forty financial institutions across Europe and the Gulf over the past two years. The responses fall into three groups.

The first says: "Interesting, but too early." These are the same people who said the same thing about AI in banking in 2022 — caught in the pilot trap.

The second says: "That is a product team problem." Which means nobody is working on it.

The third -- the smallest group -- says: "We know. We do not know what to do yet."

Here is what I tell the third group. The institution that builds longevity-native financial products first -- retirement products for 40-year horizons, health-linked insurance, biological age-indexed pricing, multi-generational wealth tools -- does not just win a product category. It wins a generational opportunity. Because once clients experience financial products designed for the way they will actually live, they will never go back to products designed for the way their grandparents died.

The convergence of longevity science, AI-driven personalization, and the sheer scale of the longevity economy creates the single largest product opportunity in financial services for the next thirty years. The science is moving. The capital is deployed. The demographics are clear. The only thing missing is the financial products.

Whoever builds them first does not just capture a market. They define it.